Table 4.
Percentage reduction in IL at the end of the study by subpopulations (FAS)
| Age | 12–15 years | 16–18 years | 19–22 years | 23–49 years |
|---|---|---|---|---|
| 2.5% BPO gel | ||||
| No. of cases | 52 | 57 | 46 | 48 |
| Median | 73.9 | 66.7 | 69.3 | 80.4 |
| Interquartile | 40.3 to 89.7 | 42.1 to 84.2 | 47.8 to 80.0 | 59.4 to 93.3 |
| 5% BPO gel | ||||
| No. of cases | 46 | 51 | 52 | 54 |
| Median | 72.8 | 72.0 | 71.9 | 78.8 |
| Interquartile | 57.7 to 84.6 | 46.2 to 83.3 | 54.7 to 85.2 | 66.7 to 86.4 |
| Placebo | ||||
| No. of cases | 57 | 54 | 58 | 32 |
| Median | 30.4 | 36.7 | 45.8 | 60.6 |
| Interquartile | −2.7 to 63.6 | 0.0 to 64.7 | 15.4 to 66.7 | 36.9 to 77.1 |
BPO, benzoyl peroxide; FAS, full analysis set; IL, inflammatory lesions.